|
Sign In to gain access to subscriptions and/or personal tools.
|
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor
Bo-qing Zhu
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
Yi-ping Sun
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
Richard E Sievers
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
Amanda EM Browne
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
Randall J Lee
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
Kanu Chatterjee
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA
William W Parmley
Division of Cardiology, Department of Medicine, University of California, San Francisco, USA, parmley@ medicine.ucsf.edu
A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion. However, the effect of a differing time course of pretreatment has not been investigated. 104 Sprague-Dawley rats were randomised to four groups: a control, and three treatment groups in which losartan (40 mg/kg/day) was administered in drinking water for one day, one week, and four weeks respectively. After different durations of pretreatment, the rats were subjected to 17 minutes of left coronary artery occlusion and 120 minutes of reperfusion. Haemodynamic variables were not significantly different between the four groups. Myocardial infarct size was unchanged after one day and one week of pretreatment (52±7, 57±6% vs. control 55±3%), but was significantly reduced by four weeks of pretreatment with losartan (38±6, p<0.05). Endothelial-dependent vasorelaxation was significantly increased by four weeks of pretreatment (-81±4 vs. -62±7%, p<0.05). As an indicator of ischaemia, vascular endothelial growth factor (VEGF) levels in ischaemic myocardium were decreased after one and four weeks of pretreatment (0.75±0.05, 0.58±0.10 vs. 1.0, p<0.05, 0.01, respectively).
In conclusion, losartan has time-dependent cardiovascular protective effects. Four weeks of pretreatment with losartan decreased infarct size and VEGF, and improved endothelial dysfunction.
Key Words: angiotensin type 1 (AT1)-receptor antagonist • myocardial infarct size • ischaemia-reperfusion • endothelial function • VEGF (vascular endothelial growth factor)
References
- Dzau VJ Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77(suppl I):14-113.[Web of Science]
- Hartman JC,Wall TM, Hullinger TG, Shebuski RJ Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.[Web of Science][Medline]
[Order article via Infotrieve]
- Zhu B.-Q, Sun Y.-P, Sievers RE et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular proteition in a rat model of ischaemia-reperfusion. J Am Coll Cardiol 2000;35:787-95.[Abstract/Free Full Text]
- Zhu B.-Q, Sun Y.-P, Sudhir K. et al. Effects of second-hand smoke and gender on infarct size of young rats exposed in utero and in the neonatal to adolescent period. J Am Coll Cardiol 1997;30:1878-85.[Abstract]
- Sievers RE, Schmiedl U., Wolfe CL et al. A model of acute regional myocardial ischaemia and reperfusion in the rat. Magn Reson Med 1989;10:172-81.[Web of Science][Medline]
[Order article via Infotrieve]
- Wong J., Chou L., Reid IA Role of AT1 receptors in the resetting of the baroreflex control of heart rate by angiotensin II in the rabbit. J Clin Invest 1993;91:1516-20.[Web of Science][Medline]
[Order article via Infotrieve]
- Matsukawa S., Keil LC, Reid IA Role of endogenous angiotensin II in the control of vasopressin secretion during hypovolemia and hypotension in conscious rabbits. Endocrinology 1991;128:204-10.[Abstract/Free Full Text]
- Hutchison SJ, Glantz SA, Zhu B-Q. et al. In-utero and neonatal exposure to secondhand smoke causes vascular dysfunction in newborn rats. J Am Coll Cardiol 1998;32:1463-7.[Abstract/Free Full Text]
- Azizi M., Guyene TT, Chatellier G., Menard J. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exper Hyperten 1997;19:937-51.
- Rodrigo E., Maeso R., Munoz-Garcia R. et al. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hyperten 1997;15:613-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Deck CC, Gaballa MA, Raya TE Relative contribution of angiotensin II, bradykinin, and prostaglandins to the renal effects of converting enzyme inhibition in rats after chronic myocardial infarction. J Cardiovasc Pharmacol 1996;28:167-74.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Milavetz JJ, Raya TE, Johnson CS, Morkin E., Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-9.[Abstract]
- Hartman JC The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 1995; 60:789-92.[Abstract/Free Full Text]
- Ju H., Zhao S., Jassal DS, Dixon IMC. Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997;35:223-32.[Abstract/Free Full Text]
- Taylor K., Patten RD, Smith JJ et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin IIreceptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998;31:654-60.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wilmink HW, Banga JD, Hijmering M., Erkelens WD, Stroes ESG, Rabelink TJ Effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999;34:140-5.[Abstract/Free Full Text]
- Goetz RM, Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clinical Science 1999;97:165-74.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Pupilli C., Lasagni L., Romagnani P. et al.Angiotensin II stimulates the synthesis and secretion of vascular permeability factor / vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-55.[Abstract/Free Full Text]
- Gruden G., Thomas S., Burt D. et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999;10:730-37.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2,
129-133 (2001)
DOI: 10.3317/jraas.2001.014
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Pourdjabbar, T. G. Parker, Q. T. Nguyen, J.-F. Desjardins, N. Lapointe, J. N. Tsoporis, and J.-L. Rouleau
Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling
Am J Physiol Heart Circ Physiol,
April 1, 2005;
288(4):
H1997 - H2005.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P.E. van Dokkum, W. B.A. Eijkelkamp, A. C.A. Kluppel, R. H. Henning, H. van Goor, M. Citgez, W. A.K.M. Windt, D. J. van Veldhuisen, P. A. de Graeff, and D. de Zeeuw
Myocardial Infarction Enhances Progressive Renal Damage in an Experimental Model for Cardio-Renal Interaction
J. Am. Soc. Nephrol.,
December 1, 2004;
15(12):
3103 - 3110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Christman, A. J. Vardanian, Q. Fang, R. E. Sievers, H. H. Fok, and R. J. Lee
Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium
J. Am. Coll. Cardiol.,
August 4, 2004;
44(3):
654 - 660.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
